Gland Pharma is a specialty injectables and contract development and manufacturing organization (CDMO) with two operating units: the base business in generic and complex injectables, and Cenexi, a European CDMO. The base business generates the bulk of profit, with U.S. revenue of INR8,290 million in Q3 FY26, up 16% year on year, and a base business adjusted EBITDA margin of 37% in that quarter. The consolidated margin was 26% because Cenexi is still ramping, but the base business margin is exceptional for manufacturing, reflecting a portfolio where top 20 U.S. products hold market shares above 25% and some exceed 40%. The competitive structure is concentrated: complex injectables require regulatory approvals and manufacturing expertise, and Gland has a strong compliance record with GMP certifications, including Cenexi's Fontenay site renewed through end of 2026.
The economics persist because of high entry barriers. Complex injectables like hormones, suspensions, peptides, and ready-to-use bags require lengthy qualification cycles with customers and regulators. Gland's cost leadership, driven by automation, alternate API suppliers, and process optimization, allows it to win GPO contracts even as U.S. prices decline; volumes grew 19% year on year in Q3 while price dropped. The CDMO side adds switching costs: customers outsource manufacturing of oncology and peptide products, and once qualified, they rarely switch. Cenexi brings capabilities Gland cannot replicate, such as herbal products and controlled substances, and its Fontenay site is set to become the largest ampoule manufacturing site in Europe. These are not commodity scale advantages but specialized, mission-critical assets that take years to replicate.
The inflection is capacity coming online and CDMO contracts converting to revenue. The cartridge fill-finish line is expanding from 40 million to 140 million units, with the new line delivered in early 2026, validation over four months, and exhibit batches ready by Q2 FY27. This capacity supports GLP-1 and insulin programs; liraglutide launched in the U.S. in January 2026, and two to three more GLP-1 contracts are being signed, with a pipeline of six to seven more. A new CDMO oncology contract, requiring INR80 crores capex, is expected to generate USD25-30 million annually starting H2 FY28, with commercialization in Q3/Q4 FY28. Biologics capacity is expanding from 8 kiloliters to 23 kiloliters. By mid-2027 to mid-2028, the base business should be growing at the guided 12-13% minimum, Cenexi should be sustainably EBITDA positive (it turned positive in Q3 FY26 with INR148 million EBITDA), and the new CDMO contract alone will add roughly INR200-250 crores of annual revenue. The RTU bag portfolio, with 20 products filed and 16 approved, adds another growth layer.
Management has walked the talk. In November 2025, they guided to mid-teens consolidated revenue growth for FY26, Cenexi EBITDA breakeven from Q3 FY26, and a base business EBITDA margin around 35%. The February 2026 call reported Q3 FY26 base business revenue growth of 16% (ex-Cenexi), Cenexi positive EBITDA of INR148 million, and base business adjusted EBITDA margin of 37%, beating the margin guidance. They reaffirmed confidence in sustaining FY26 momentum and maintained the base business growth floor of 12-13%. Capital allocation is disciplined: FY26 capex is about INR2,500 million for the base business and EUR25 million for Cenexi, with a five-year plan of INR2,000 crores for the base business. They have not raised guidance, but they have consistently delivered on milestones like the liraglutide launch and the cartridge line timeline. The only miss was a delay in dalbavancin approval, with additional data submitted in January and a goal date in February 2026.
The earnings path is quantifiable. Base business revenue grew 16% in Q3 FY26 to INR11,790 million; if it sustains 12-13% growth, that alone adds over INR1,500 million annually. Cenexi, which lost EUR11 million in H1 FY25, turned to positive EBITDA in Q3 FY26 and should contribute incremental profit as utilization rises. The new CDMO contract adds USD25-30 million from FY28, and cost savings programs are expected to deliver 1-2 percentage points of margin improvement. The key watchpoint is execution on capacity utilization: the cartridge line must ramp to 140 million units, and the CDMO contracts must convert on schedule. The biggest falsifier would be a delay in the oncology CDMO commercialization or a failure to sign additional GLP-1 contracts, which would push the revenue inflection out. Also, U.S. price erosion, though currently flat, could accelerate. The tension between a 37% base margin and a 26% consolidated margin is structural, not operational, and resolves as Cenexi scales.
companyname: Gland Pharma Limited ticker: GLAND sector: Pharmaceuticals – Sterile Injectables / CDMO Gland Pharma is a Hyderabad-based sterile injectables manufacturer that works almost entirely B2B. It does not build consumer brands. It either files its own ANDAs and licenses them to marketing partners who sell to hospitals, or it manufactures on behalf of pharma companies as a CDMO. Founded in 1978, the company runs 11 manufacturing facilities, including four from its French/Belgian subsidiar...
Read the full report →capex, margin expansion, regulatory approval, new product segment
FY28 CDMO project guided at USD25-30 million annual revenue starting H2 FY28 driven by new capacity ramp-up
Guidance no_dataGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Gland Pharma Limited and 4,900+ companies.
5-day free pass. No card required.